Purpose: This study was designed to present the treatment outcomes with Wingspan stent angioplasty of high-grade intracranial vertebrobasilar artery (VBA) stenosis in symptomatic patients.
Methods: Between 2007 and 2010, the records of 30 patients with 31 intracranial high-grade VBA stenoses (all ≥ 70%) who underwent elective stenting due to the failure of medical therapy were retrospectively reviewed. Clinical evaluation was performed based on the modified Rankin scale and the National Institutes of Health Stroke Scale.
Results: In all cases, the stent deployment was technically successful. The mean stenosis decreased significantly from 82.28 ± 8.02% (range, 72-99%) to 11.18 ± 7.28% (range, 0-25%) after stent-assisted angioplasty (P < 0.05). Periprocedure complications occurred in 3 (10%) of 30 patients; there were 2 cases of perforator strokes and 1 case of transient flow insufficiency with stent overlap. Clinical follow-up (mean, 17.81 ± 11.49 months; range, 5-40 months) was available for 27 patients, and angiographic follow-up (mean, 9.95 ± 5.74 months, range, 5-20 months) was available for 19 patients. Only one case demonstrated recurrent symptoms with restenosis (≥ 50%). There were no recurrent ischemic events and no cases of restenosis in the other patients.
Conclusions: According to our data, the Wingspan stent for symptomatic intracranial VBA stenoses is a safe and efficacious treatment alternative in cases with recurrent symptoms despite medical therapy. However, the improvement of outcome requires the reduction in the rate of procedure-related complications and long-term outcomes still have to be demonstrated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00270-011-0163-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of safety and efficacy of intracranial self-expanding drug-eluting stents for symptomatic intracranial atherosclerotic stenosis: a prospective, multicentre, randomised controlled, superiority clinical trial protocol.
BMJ Open
November 2024
Department of Cerebrovascular Disease, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan, China
Background: In-stent restenosis (ISR) is a crucial factor that affects the long-term efficacy of intracranial bare metal stent (BMS) implantation for intracranial atherosclerotic stenosis (ICAS). Patients with intracranial ISR are at a high risk of recurrent ischaemic events. The NOVA intracranial drug-eluting stent (DES) trial demonstrates that a DES can reduce ISR and stroke recurrence after intracranial bare stent implantation.
View Article and Find Full Text PDFInvestigator-initiated clinical trial of stabilizer device: A novel intracranial exchange guidewire for neuroendovascular treatments.
Interv Neuroradiol
August 2024
Division of Interventional Neuroradiology, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA.
Article Synopsis
- The study evaluated a new device called the Stabilizer, designed to enhance the safety and efficacy of neuroendovascular procedures that require exchanging medical instruments, which can be risky due to potential vessel injury.! -
- Conducted across nine centers in Japan, the trial involved 31 patients with conditions like intracranial aneurysms and artery stenosis, with the Stabilizer achieving a 100% technical success rate and no device-related complications.! -
- The findings of this first multicenter trial underscore the Stabilizer's potential as a reliable tool in managing complex neuroendovascular cases where traditional exchange methods might pose challenges.!
DRug-coated Balloon for Endovascular treatment of sYmptOmatic intracraNial stenotic Disease (DR. BEYOND): the protocol of a multicentre randomised trial.
Stroke Vasc Neurol
July 2024
Interventional Neuroradiology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Background: Although endovascular stenting is considered an effective and safe therapeutic option for symptomatic intracranial atherosclerotic disease (sICAD), an elevated rate of restenosis remains an important issue for the conventional bare-metal stent (BMS). Recent evidence from observational studies suggests that applying drug-coated balloons (DCB) in sICAD may decrease restenosis occurrence. Additional large randomised studies are warranted to provide firmer evidence and to determine which patients would benefit most from DCB.
View Article and Find Full Text PDFPercutaneous transluminal angioplasty and stenting for severe stenosis of the intracranial carotid artery and its branches: Comparison of the Wingspan stent vs the Credo stent.
J Chin Med Assoc
September 2024
Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Article Synopsis
- A study compared the Wingspan and Credo stent systems for treating severe intracranial artery stenosis in patients who did not respond to medication.
- A total of 29 patients were analyzed, with no significant differences in technical success, safety, or outcomes between the two stent systems.
- Both stent systems showed promising results, but further research is needed to confirm these findings on a larger scale.
Clinical experience in intracranial stenting of Wingspan stent system under local anesthesia.
Front Neurol
March 2024
Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan.
Objective: The use of endovascular treatments for symptomatic intracranial atherosclerosis disease (ICAD) remains contentious due to high periprocedural complications. Many centers resort to general anesthesia for airway protection and optimal periprocedural conditions; however, this approach lacks real-time monitoring of patients' neurological status during procedures. In this study, we employed intracranial stenting with the Wingspan system under local anesthesia to address this challenge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!